« Return to News | Awards & Advancement

Astellas adds four to team

Tuesday, May 3, 2011 12:33 PM

Astellas Pharma Global Development, a subsidiary of Tokyo-based Astellas Pharma, welcomes four new industry leaders to its team.

Stephen Eck, M.D., Ph.D., has been promoted to vice president, head of medical oncology, and has more than 28 years of experience focused primarily in oncology research. Eck was most recently the vice president of translational medicine & pharmacogenomics at Eli Lilly.

Karen Reeves, M.D., is now vice president, global head of medical science, has more than 16 years of experience in phase 1 through 4 drug development in several therapeutic areas. She was a former vice president at Pfizer.  

Mark Weinberg, M.D., MBA, has been promoted to therapeutic area head for CNS and pain and has more than 12 years of experience in the pharmaceutical industry, working across multiple therapeutic areas.  He was most recently at Lundbeck where he focused on CNS. 

Bernhardt Zeiher, M.D., is now vice president, therapeutic area leader of inflammation, immunology and infectious diseases, and has more than 13 years of experience in the pharmaceutical industry and most recently came from Pfizer.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.